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I In nt tr ro od du uc ct ti io on n
The development of a prophylactic and/or therapeutic DNA
vaccine for humans has been shown to be more difficult than
anticipated. This has often been attributed to problems
related to delivery. However, things are slowly changing in
the DNA vaccine arena. Today, four DNA vaccines have been
licensed for veterinary use. Importantly, at the DNA
Vaccines 2008 meeting the first reports with early positive
data from human studies using in vivo electroporation were
presented. In parallel with this, new immunological
approaches have highlighted the importance of studying the
quantity and quality (polyfunctionality?) of DNA vaccine-
activated T cells. These may allow us to better understand
the relation between in vitro-determined immune responses
and  in vivo protection and functionality. With these
cautiously encouraging data, we may hope to see rapid
advances in the field of DNA vaccines over the coming years.
A Ai im ms s   a an nd d   m me ee et ti in ng g   f fa ac ct ts s
The DNA Vaccines 2008 meeting [http://www.
bioconferences.com/CONFERENCES/DNA/] was held at
the Tropicana Resort and Casino, Las Vegas, NV, USA,
December 9-11, 2008. The main goals of the meeting were
to gather as many scientists, clinicians, and academic and
industrial investigators as possible working in the field of
DNA vaccines to report and discuss their latest break-
throughs. Moreover, the meeting aimed for more intensive
interactions between researchers in academia and bio-
technology/pharmaceutical companies.
The meeting gathered approximately 150 attendees from
academia, biotechnology and pharmaceutical companies,
and media representatives. At the meeting, over 40 talks and
around 60 posters were presented. In this report a few
highlights regarding clinical studies have been selected.
T Th he e   c cu ur rr re en nt t   s st ta at tu us s   i in n   t th he e   f fi ie el ld d   o of f   D DN NA A   v va ac cc ci in ne es s
The meeting aim was to gather academic and industrial
researchers interested in DNA vaccines. This aim was
certainly fulfilled. A major obstacle in the DNA vaccine field
has been the observation that although DNA vaccines work
well in small animals, they do less well in larger animals and
in humans. It was therefore no surprise that many of the
presentations this year focused on optimizing delivery,
particularly using in vivo electroporation. Many of the
industrial attendees were from companies involved in
developing this technique. One of the take-home messages
from the meeting, as very well summarized in the panel
debate, was a desire to get DNA vaccines to a stage where
there is undisputed evidence of clinically beneficial effects in
humans. This meeting showed that the field is now a step
closer to reaching this goal. Several preclinical studies in
non-human primates and clinical studies have shown
encouraging results in the field of DNA vaccination.Important evidence for success of the DNA vaccine field is,
in particular, the progress in the animal health product
portfolio. To date we have at least four licensed animal
DNA-based products on the market, which indicates that
the field is moving forward. Dr Steve Chu, from Fort Dodge
Animal Health, Wyeth (Overland Park, KS, USA) presented
results from the world’s first licensed DNA vaccine against
equine West Nile virus (EWNV) for horses. He showed that
two intramuscular doses of the DNA vaccine provided 12-
month immunity against EWNV. To maintain long-term
protection against EWNV an annual revaccination was
needed. The DNA vaccine was importantly shown to be safe
and tolerable. Moreover, Ruxandra Draghia-Akli, MD, from
VGX Pharmaceuticals Inc. (Blue Bell, PA, USA), presented
results from the world’s first licensed porcine growth
hormone-releasing hormone (GHRH) supplementation
product, encoded by a DNA vaccine given in combination
with electroporation. A single dose of the GHRH-expressing
DNA vaccine had visible effects in pigs for 12 to 18 months
post vaccination.
I Im mp pr ro ov ve ed d   i im mm mu un no og ge en ni ic ci it ty y   i is s   n ne ee ed de ed d   f fo or r   d de ev ve el lo op pm me en nt t
o of f   a a   s su uc cc ce es ss sf fu ul l   D DN NA A   v va ac cc ci in ne e
So far no DNA vaccine is close to being licensed for human
use and the biggest unmet goal today is the lack of proof-of-
concept regarding efficacy in humans. This is somewhat
surprising since it is a widely accepted view that DNA
vaccines have several advantages over conventional vaccines.
In particular, they are easy to produce and manufacture, the
time from bench-to-clinic is short, and they have, so far, no
problems related to vector immunity. During the past
15 years of DNA vaccine development, several unanticipated
problems have arisen, where the failure of activating potent
immune responses in humans has become a major issue.
A general consensus regarding HIV vaccines was that from
now on they will be benchmarked with the Merck vaccine
used in the recently terminated STEP (HIV Vaccine Trial
Network, Study 502) trial. Michael Betts, assistant professor
at University of Pennsylvania (PA, USA), gave a presentation
where he discussed anti-vector immunity and different
reasons for the failure of the STEP trial. The conference
chairman, David Weiner, also a professor at University of
Pennsylvania, (PA, USA), highlighted that in order to
succeed in the development of prophylactic and/or thera-
peutic DNA vaccines for humans, several steps need to be
taken into consideration. The DNA vaccine needs to be
optimized in all possible ways, it needs to be delivered
effectively, and, if required, molecular adjuvants such as
interleukin-12 (IL-12) can be added. Dr Weiner showed data
suggesting that all these factors combine and contribute in
different ways to the immunogenicity and effect of the
vaccine. Dr Michael Egan, of Profectus Biosciences,
Baltimore (MD, USA), provided data along the same lines
from testing HIV vaccines in non-human primates, showing
that both in vivo electroporation and the co-delivery of an
IL-12 plasmid have beneficial effects on the priming of
immune responses. In particular, the polyfunctionality of the
responses improved when using this combination. These
differences may have been missed if the polyfunctionality
had not been determined, highlighting the potential
importance of this type of readout.
D DN NA A   v va ac cc ci in ne es s   s st ta ar rt ti in ng g   t to o   s sh ho ow w   s so om me e   e ef ff fe ec ct ts s   i in n   h hu um ma an ns s
Results from several promising ongoing phase I and II clinical
studies were presented at the meeting. In these trials many of
the above-mentioned problems had been considered.
Professor Freda Stevenson, from the University of
Southampton (UK), discussed the data from a phase I/II
trial on an epitope-specific DNA vaccine for prostate cancer
delivered by in vivo electroporation. She highlighted that
although the cytotoxic T lymphocyte (CTL) responses were
low when measured directly ex vivo, they could effectively
expand memory CTLs by in vitro re-stimulation. The trial is
still under way. Professor Richard Heller, from the Frank
Reidy Research Center for Bioelectrics, Old Dominion
University (VA, USA), presented results from a phase I study
of a DNA vaccine encoding IL-12 administered in combina-
tion with electroporation as an immunotherapy against
metastatic melanoma. Heller’s results showed safety and
tolerability as well as durable partial and complete regres-
sion of treated melanoma lesions. Ten out of 24 enrolled
patients showed a therapeutic effect. Matti Sällberg,
professor at Karolinska Institutet (Sweden), presented
results from a phase I/II study, where a DNA vaccine
against hepatitis C virus (HCV) was delivered via in vivo
electroporation to treat naïve chronic HCV-infected
patients. This study provided data supporting good safety
and tolerability of the treatment. Importantly, the study
showed an activation of HCV-specific immune responses,
and transient reductions in the viral load of up to 2.4 log10
in four out of six patients in the two highest-dose groups. Dr
Mart Ustav, from FIT Biotech (Tampere, Finland),
presented early results of a phase II trial with a DNA
vaccine against HIV-1 delivered by the biojector. The
vaccine showed good safety and tolerability as well as
effects on the viral load and increased CD4+ T-cell counts
compared to placebo controls.
C Co on nc cl lu ud di in ng g   r re em ma ar rk ks s
The above-mentioned studies demonstrate optimism that
DNA vaccination may actually work in humans. Although
there may be a long way to go, these initial data indicate that
DNA vaccination in humans has a therapeutic effect on
cancer and infectious diseases. The DNA Vaccines meeting
of 2008 suggests that we may see more rapid advances in
clinical trials, with the Holy Grail being a successful DNA
vaccine in the not too distant future.
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CTL, cytotoxic T lymphocyte; EWNV, equine West Nile
virus; GHRH, growth hormone-releasing hormone; HCV,
hepatitis C virus; HIV, human immunodeficiency virus;
IL-12, interleukin-12.
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